EUVIMEDEUVIMED entdecken
Open Access

Multiomic integration reveals subtype-specific predictors of neoadjuvant treatment response in breast cancer

Zongchao Mo iD, Mei Yang, Zhihan Zhu iD, Minghao Wang iD, Haoyu Wang, Zhanye Zhang iD, Shanshan Lyu, Fangping Xu, Haixia Shang iD, Huan Lin iD, Zeyan Xu iD, Suyun Li und 5 weitere

Science Advances · 04.07.2025 · 11 (27)

DOI: 10.1126/sciadv.adu1521 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 04.07.2025. Verfasst von Zongchao Mo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Life Science, Department of Chemical and Biological Engineering, and State Key Laboratory of Nervous System Disorders, The Hong Kong Univ…. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant therapy has been widely used in breast cancer, but treatment response varies among individuals. We conducted multiomic profiling on tumor samples from 149 Chinese patients with breast cancer across ER − HER2 + , ER + HER2 + , and ER − HER2 − subtypes, categorizing outcomes as pathologic complete response (pCR; n = 81) or residual disease (RD; n = 68). We identified distinct molecular features linked to pCR in each subtype: elevated cell proliferation in patients with ER − HER2 − pCR, higher CDKN2A methylation in patients with ER − HER2 − RD, increased KIT methylation in patients with ER − HER2 + RD, and MAP4K1 hypermethylation in patients with ER + HER2 + RD. These findings were subsequently validated in independent datasets. By integrating clinical and multiomic data, we developed MOPCR, a subtype-specific machine learning model that outperformed single-omic approaches in predicting treatment response. MOPCR demonstrated potential generalizability across cohorts and provided preliminary stratification of patient subgroups with higher pCR probability, offering valuable insights for precision cancer management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoadjuvant TherapyHumansFemaleDNA MethylationErb-b2 Receptor Tyrosine KinasesMiddle AgedTreatment OutcomeBiomarkers, TumorMachine LearningReceptors, EstrogenGene Expression Regulation, NeoplasticPrognosisGene Expression Profiling

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorReceptors, Estrogen

Autor:innen und Institutionen

  • Division of Life Science, Department of Chemical and Biological Engineering, and State Key Laboratory of Nervous System Disorders, The Hong Kong University of Science and Technology, Hong Kong, SAR, China.
  • SIAT-HKUST Joint Laboratory of Cell Evolution and Digital Health, HKUST Shenzhen-Hong Kong Collaborative Innovation Research Institute, Futian, Shenzhen 518000, China.
  • Department of Breast Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
  • Department of Breast Cancer, Cancer Centre, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.
  • Department of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.
  • Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.

ORCID-Profile: Zongchao Mo, Zhihan Zhu, Minghao Wang, Zhanye Zhang, Haixia Shang, Huan Lin, Zeyan Xu, Xiaobo Chen, Kun Wang, Changhong Liang, Jiguang Wang, Zaiyi Liu

Zitieren

APA

Mo, Z., Yang, M., Zhu, Z., Wang, M., Wang, H., Zhang, Z., Lyu, S., Xu, F., Shang, H., Lin, H., Xu, Z., Li, S., Chen, X., Wang, K., Liang, C., Wang, J., & Liu, Z. (2025). Multiomic integration reveals subtype-specific predictors of neoadjuvant treatment response in breast cancer. Science Advances, 11(27). https://doi.org/10.1126/sciadv.adu1521

Vancouver

Mo Z, Yang M, Zhu Z, Wang M, Wang H, Zhang Z, et al. Multiomic integration reveals subtype-specific predictors of neoadjuvant treatment response in breast cancer. Science Advances. 2025;11(27). doi:10.1126/sciadv.adu1521

BibTeX
@article{Mo2025,
  author = {Mo, Zongchao and Yang, Mei and Zhu, Zhihan and Wang, Minghao and Wang, Haoyu and Zhang, Zhanye and Lyu, Shanshan and Xu, Fangping and Shang, Haixia and Lin, Huan and Xu, Zeyan and Li, Suyun and Chen, Xiaobo and Wang, Kun and Liang, Changhong and Wang, Jiguang and Liu, Zaiyi},
  title = {Multiomic integration reveals subtype-specific predictors of neoadjuvant treatment response in breast cancer},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {27},
  doi = {10.1126/sciadv.adu1521}
}
Kostenlos starten →